Abstract: The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.

Abstract: The present invention provides a biomolecular carrier of pharmaceuticals, comprising: a biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell; and a pharmaceutical. The present invention also provides a method of treating a pathophysiological state in an individual in need of such treatment, comprising the steps of: irradiating a target tissue or organ in said individual; and administering to said individual the biomolecular carrier disclosed herein.

Abstract: A method and system for organizing a package involving identifying an asset within an application, wherein the asset is determined by an asset boundary and the asset contains a logic/data part and an extended environment part; identifying the package within the application, wherein the package is a logical division of the application and wherein the package includes a plurality of assets; determining a package boundary identifying the scope of the package, wherein the package boundary may be determined by the asset boundary of at least one asset in the package; and organizing the package according to the package boundary, wherein the package including at least two assets.

Abstract: The nucleotide sequences of the genomes of eleven molecular clones for non-subtype B isolates of human immunodeficiency virus type 1 are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

Abstract: The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies.

Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.

Abstract: A component distribution server (CDS) system connected to at least one network through at least one respective network interface includes: a package specification process that receives at least one package, the packages being subparts of at least one application program from at least one enterprise information system (EIS), the packages having at least one assets, each asset having an asset type and at least two asset layers, a first asset layer being a logic/data layer and a second asset layer being an extended environment layer, the logic/data layer having information that includes a function of the asset and the extended environment layer being a subset of the EIS and having portions of the EIS necessary to support the respective logic/data layer; a process adapter process that translates at least one of the assets layers so that the asset performs the asset function on at least one target base environment of at least one target computer; and a target process that changes the at least one of the layers of

Abstract: The present invention provides a method, referred to as CpG retrieval, to overcome incomplete bisulfite modification of DNA recovered from formalin-fixed tissue samples. The method involves boiling deparaffinized tissue samples in citrate buffer, followed by DNA extraction for promoter methylation analysis. In general, the extracted DNA is further modified by sodium bisulfite and then subjected to a method of promoter methylation analysis. The present invention also reports that hypermethylation of ataxia-telangiectasia-mutated gene promoter is correlated with decreased overall survival in patient with head and neck squamous cell carcinoma.

Abstract: Human UDP-glucuronosyltransferase 2B7 (UGT2B7) protein expression is limited to ovarian surface epithelium cells and that this protein is not present in tumors arising from this cell layer. UDP-glucuronosyltransferase 2B7 protein accumulates in cells when the cells enter stationary phase and growth inhibition. UGT2B7 protein is not expressed in exponentially growing ovarian tumor cells. Overexpression of UGT2B7 protein in human ovarian tumor cells results in cell growth arrest, significant reduction of lipid content and changes in cell morphology. Thus, active UGT2B7 protein expression in tumor cells can be used to decrease cell proliferation and to treat various cancers, whereas UGT2B7 mRNA expression, protein expression and/or enzymatic activity can be used as a tumor specific marker in diagnostic procedures.

Abstract: The present invention describes the cloning and molecular and cellular characterization of a novel protein with homology to the IL-17 receptor. The gene was cloned by virtue of its proximity to a common site of retroviral integration in a murine acute myeloid leukemia. The gene described herein possibly codes for a novel interleukin receptor that binds an as yet unidentified cytokine ligand, and may be useful in cancer diagnostics and therapies that rely on immune system modulation.

Abstract: The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.

Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.

Abstract: The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone receptor type 1 (mCRH-R1c, 1e and 1f). The data indicate that polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, external stress (UV), and that cAMP dependent pathways and TPA may regulate CRH-R1.

Abstract: The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein.

Abstract: The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.

Abstract: The present invention provides a purified, homogeneous plant enzyme that adds a ?-1,2-linked xylose to the ?-linked mannose on the N-linked oligosaccharides of storage glycoproteins. This ?1,2-xylosyltransferase was purified from the microsomal fraction of soybean cells approximately 51,000-fold. Also provided is an antibody recognizing this ?1,2-xylosyltransferase.

Abstract: The present invention demonstrates the biological function of a newly identified osteoclast-secreted protein. This protein, mim-1, has sequence homology with but is distinct from a previously identified neutrophil chemokine protein. Mim-1 may be a key signaling protein secreted by osteoclasts that regulates recruitment and/or differentiation of osteoblast and osteoclast precursor cells. This protein may also serve to maintain osteoclasts in a relatively inactive state prior to secretion. This mechanism is essential for regulating the mass and structural integrity of bone. This protein or an analog and/or antagonists of this protein will have potential therapeutic potential in the treatment of a variety of pathological bone diseases including osteoporosis and metastatic bone diseases.

Abstract: Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and/or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and/or diagnostic agents.

Abstract: The present invention provides methods for determining fluorescence lifetime of a fluorophor or an optical sensor using frequency domain gated detection. The method comprises the steps of exciting the fluorophor with frequency modulated light from a pulsed light source, gating a photodetector during excitation of the fluorophore, detecting light emitted from the fluorophor with the photodetector, where the emission light exhibits a phase shift in frequency from that of the excitation light, converting the detected excitation light to an amplified electric signal, and evaluating the amplified electric signal as a measure of fluorescence lifetime of the fluorophor. Also provided is a device with which to use the methods disclosed herein.

Abstract: The present invention provides a transgenic animal expressing the reporter gene, luciferase, driven by a promoter (e.g. the E2F1 promoter) that acts as a sensor of cell cycle. The luciferase substrate, luciferin, emits light when metabolized, and the light is transmitted through mammalian tissues. Therefore, the transgenic animal model of the present invention allows for monitoring of areas of major cell cycle activity, a characteristic of cancer cells, under adequate visualization conditions. These transgenic animals are useful as in vivo models for testing preventative measures for cancer as well as for testing novel therapeutic modalities.